相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis
M. C. Ovejero-Benito et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis A Randomized Clinical Trial
Selma Atalay et al.
JAMA DERMATOLOGY (2020)
Injection site reactions with the use of biological agents
Elena Thomaidou et al.
DERMATOLOGIC THERAPY (2019)
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy
G. Carretero et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis
Rosa M. Romero-Jimenez et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Dosage adjustments in patients with psoriasis on adalimumab - a retrospective chart review
E. B. Lee et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
regThe patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study
Lise M. Verhoef et al.
RHEUMATOLOGY (2018)
Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach
Zachary Munn et al.
BMC MEDICAL RESEARCH METHODOLOGY (2018)
Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity
Weiyu Ye et al.
DRUGS (2018)
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature
Igor Snast et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study
M. Esposito et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Vibeke Strand et al.
BIODRUGS (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Adalimumab Dose Tapering in Psoriasis: Predictive Factors for Maintenance of Complete Clearance
Katharina Hansel et al.
ACTA DERMATO-VENEREOLOGICA (2017)
Efficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocol
Rosa Maria Romero-Jimenez et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study
Stefano Piaserico et al.
ACTA DERMATO-VENEREOLOGICA (2016)
Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest
K. Reich et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2015)
Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry
P. Gisondi et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice
Jose-Manuel Carrascosa et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Does Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting
O. Baniandres et al.
ACTAS DERMO-SIFILIOGRAFICAS (2015)
Antidrug antibodies in psoriasis: a systematic review
L. Hsu et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre
A. Lopez-Ferrer et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment
T. Taniguchi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life
Lluis Puig et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2013)
Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre
C. Fotiadou et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2012)
Adverse drug reactions to biologics
Kathrin Scherer et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2010)
Low-dose etanercept therapy in moderate to severe psoriasis in Korean
Jung Im Na et al.
JOURNAL OF DERMATOLOGY (2008)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Psoriasis assessment tools in clinical trials
SR Feldman et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
分享论文
